undamentalytics Newsletter
Sign in

Acadia Healthcare Company, Inc. (ACHC) stock

Add to watchlist

Add holding +

NASDAQ: ACHC Nasdaq Health Care Facilities Next results ~November 4, 2026

D Fundamentals grade

Acadia Healthcare Company, Inc. is a US-listed company in the health care facilities industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$36

Valuation models combined (3)

Base case. Range ~$22–$44. Weighted average of 3 models (growth cash-flow model, forward price-to-earnings vs peers, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Acadia Healthcare Company, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds157 adding, 144 cuttingOf 70 active managers that changed their stake, 30 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Acadia Healthcare files

Where Acadia Healthcare stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $3.37bn, up 4.3% on a year earlier, slower than the 6.8% growth a quarter earlier. Free-cash-flow margin rose to -4.0% from -9.6% a year earlier. Operating margin widened to 28.7% from 21.2%. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 1 of our 6 financial-health checks. Our growth cash-flow model value is $40.36 a share, against a share price of $31.22.

Source: 10-Q filed July 28, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Acadia Healthcare Company, Inc.'s trailing-twelve-month revenue grew 4.3% year on year, with a free-cash-flow margin of -4.0%. Where it lags: net margin of -33.4% ranks 13 of 13 health care facilities companies we cover.

Current signal Net margin compressing: TTM net margin fell to -33.4%, down 37.8pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • High operating margin. 28.7% of revenue is left as operating profit.
  • Margins widening. Operating margin is up 7.5 points on a year ago.
  • Shrinking share count. Diluted shares fell 1.1% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.
  • Estimates rising. Analysts' consensus for next year's earnings per share has risen 5.0% over 90 days.

Things to watch

  • Burning cash. Free cash flow was -4.0% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 64% and a beta of 0.9 against the S&P 500.
  • Growth easing. The growth rate is 2.5 points lower than a quarter earlier.
  • Below peers: net margin. Net margin of -33.4% ranks 13 of 13 health care facilities companies we cover (median 4.8%).
  • Below peers: revenue growth. Revenue growth of 4.3% ranks 11 of 13 health care facilities companies we cover (median 14.0%).
  • Heavily shorted. 34.5% of the shares available to trade are sold short (13.2 days of average volume to cover).

Latest results: FY2026 Q2

Filed July 28, 2026
Earnings per share
$0.38 against an average estimate of $0.35: beat by 9.7%
Revenue
$866m, down 0.4% on a year earlier
Share reaction
-15.8% in the first session after the results on July 28, 2026, against -1.3% for the S&P 500
Guidance given
revenue $3.4bn to $3.45bn (Full Year 2026); adjusted EBITDA $590m to $615m (Full Year 2026)
Next report
November 4, 2026; average EPS estimate $0.46

Acadia Healthcare's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.1%
  • 1 week-5.5%
  • 1 month+5.6%
  • This year+108.7%
  • 1 year+37.8%
  • 5 years-52.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.4B
Net margin
-33.4%
EPS (TTM, diluted)
$-12.42

Growth

Revenue growth
+4.3%
Change in growth rate
−2.5 pts
Share count change
−1.1%

Cash

Free cash flow (TTM)
-$134M
FCF margin
-4.0%
Stock pay % of revenue
0.9%

Earnings

Last results
July 28, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results
  5. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Acadia Healthcare Company, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Acadia Healthcare Company, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.1%: the 10-year Treasury yield (4.9%) plus a beta of 0.93 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$41 ~$24–$54 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$22 ~$17–$36 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$0.2 Left out: out of range vs price (0.01x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$44 ~$45–$61 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$36 ~$22–$44 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Acadia Healthcare Company, Inc. with Health Care Facilities in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$33.10$32.63$25.71$33.22$50.26$60.70$82.32$77.76$39.65$14.19$29.62
Market value$2.8bn$2.8bn$2.2bn$2.9bn$4.5bn$5.5bn$7.5bn$7.1bn$3.7bn$1.3bn$2.7bn
+ Net debt (− = net cash)$3.3bn$3.2bn$3.2bn$3.1bn$2.8bn$1.4bn$1.3bn$1.3bn$1.9bn$2.4bn$2.2bn
Enterprise value$6.1bn$6.1bn$5.4bn$6.0bn$7.2bn$6.9bn$8.8bn$8.4bn$5.5bn$3.7bn$4.9bn
Multiples
Price / sales 1.0x1.0x1.2x1.5x2.1x2.4x2.9x2.4x1.2x0.4x0.8x
Price / earnings n/m14.2x—26.8x—28.9x27.6x—14.3x——
Price / free cash flow 52.7x22.7x14.0x29.1x10.3x42.5x89.3x185.1x———
EV / EBITDA 8.3x8.1x8.1x8.9x———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

31 /100

Weak moat

How hard Acadia Healthcare's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median 0.8% of total assets over 10 years.

  • Durability 0 / 20

    Net margin has been a median 4.3%; its worst year was -33.4%.

  • Cash conversion 9 / 20

    Free cash flow was positive in 6 of 9 years, at a median 3.8% of revenue.

  • Discipline 16 / 20

    The diluted share count rose 1.2% over five years; stock-based pay has been a median 1.1% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $878m and EPS of $0.46 (range $0.39 to $0.55) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $1.55 −22% $3.4bn +4%
Next $1.85 +19% $3.6bn +6%

Next year's EPS estimate has moved +5.0% in 90 days, across 13 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.0% on 90 days ago. In the last 30 days, 1 analyst raised Acadia Healthcare Company, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Acadia Healthcare Company, Inc., last 90 days
$1.50 $1.60 $1.70 $1.80 $1.90 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $1.52 Current fiscal year, 60 days ago: $1.55 Current fiscal year, 30 days ago: $1.55 Current fiscal year, 7 days ago: $1.55 Current fiscal year, Now: $1.55 $1.55 Next fiscal year, 90 days ago: $1.76 Next fiscal year, 60 days ago: $1.82 Next fiscal year, 30 days ago: $1.85 Next fiscal year, 7 days ago: $1.85 Next fiscal year, Now: $1.85 $1.85

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $1.52$1.76
60 days ago $1.55$1.82
30 days ago $1.55$1.85
7 days ago $1.55$1.85
Now $1.55$1.85

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 $0.35 $0.38 +9.7%
Mar 2026 $0.26 $0.37 +39.7%
Dec 2025 $0.01 $0.07 +593.1%
Sept 2025 $0.66 $0.72 +9.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 28, 2026
  • Revenue Full Year 2026 $3.4bn to $3.45bn
    “Revenue $3.40 to $3.45 billion $3.37 to $3.45 billion” source
  • Adjusted earnings per diluted share Full Year 2026 $1.45 to $1.60 Non-GAAP
    “Adjusted earnings per diluted share $1.45 to $1.60 $1.35 to $1.60” source
  • Adjusted EBITDA Full Year 2026 $590m to $615m Non-GAAP
    “Adjusted EBITDA $590 to $615 million $580 to $615 million” source
  • Operating Cash Flow Full Year 2026 $350m to $400m
    “Operating Cash Flow $350 to $400 million $285 to $325 million” source
  • Capital expenditures Full Year 2026 $235m to $255m
    “Capital expenditures $235 to $255 million $255 to $280 million” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

14 analysts, Nov 2026
Buy857%
Hold536%
Sell17%

Monthly trend

  1. Nov 2026265114
  2. Oct 2026265114
  3. Sep 2026175114

Counts of recommendations published by analysts covering Acadia Healthcare Company, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
34.5%
of tradable shares
Days to cover
13.19
at average volume
Short interest, 1 month
−3%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.5%
of shares
Employees
25,000
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +37.8%

$21.50 on October 31, 2025 to $29.62

ThenNowEffect
Revenue (last 12 months) $3.2bn $3.4bn +4.3%
P/S multiple 0.6x 0.8x +30.7%
Share count 92m 91m +1.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −59.0%

$72.24 on November 3, 2023 to $29.62

ThenNowEffect
Revenue (last 12 months) $2.8bn $3.4bn +21.2%
P/S multiple 2.4x 0.8x −66.6%
Share count 92m 91m +1.1%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ACHC+21%+36%−6%−49%−64%+109%
Industry peers (median)+17%−9%+14%+17%+31%+4%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ACHC58%58%42%25%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ACHC−21%−17%−22%−58%−70%−24%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 87% from November 30, 2022 to January 16, 2026. Getting back needed a 663% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$11.68 – $35.61
From 52-week high
−16.8%
vs 50-day average
+1.7%
vs 200-day average
+14.4%
Volatility (1 year)
65%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±13.2%
After a week
4 up, 8 down
typical move ±12.2%
After a month
4 up, 8 down
typical move ±17.0%
Results releasedNext dayS&P 500 next day5 days21 days
July 28, 2026 −15.8% −1.3% −2.6% −5.9%
April 29, 2026 −6.1% +1.0% −8.3% −15.9%
February 25, 2026 +29.8% +0.3% +40.2% +38.9%
January 13, 2026 −11.3% −0.7% +8.3% +20.1%
November 5, 2025 −1.9% −0.7% −15.7% −25.1%
August 5, 2025 −15.8% +0.3% −4.9% +10.7%
May 12, 2025 +13.0% +4.0% +5.2% −4.5%
February 27, 2025 −26.9% −0.1% −27.0% −26.5%
January 13, 2025 −1.2% +0.3% −1.2% −8.1%
October 30, 2024 −17.3% −2.3% −17.7% −21.3%
July 31, 2024 +10.0% +0.2% +5.0% +20.0%
May 1, 2024 −9.8% +0.6% −10.7% −6.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Acadia Healthcare Company, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Acadia Healthcare Company, Inc.
$2.8B $3B $3.2B $3.4B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $2.9B Revenue (TTM), FY23 Q4: $2.9B Revenue (TTM), FY24 Q1: $3B Revenue (TTM), FY24 Q2: $3.1B Revenue (TTM), FY24 Q3: $3.1B Revenue (TTM), FY24 Q4: $3.2B Revenue (TTM), FY25 Q1: $3.2B Revenue (TTM), FY25 Q2: $3.2B Revenue (TTM), FY25 Q3: $3.3B Revenue (TTM), FY25 Q4: $3.3B Revenue (TTM), FY26 Q1: $3.4B Revenue (TTM), FY26 Q2: $3.4B $3.4B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $2.9B
FY23 Q4 $2.9B
FY24 Q1 $3B
FY24 Q2 $3.1B
FY24 Q3 $3.1B
FY24 Q4 $3.2B
FY25 Q1 $3.2B
FY25 Q2 $3.2B
FY25 Q3 $3.3B
FY25 Q4 $3.3B
FY26 Q1 $3.4B
FY26 Q2 $3.4B
Revenue growth, TTM YoY Acadia Healthcare Company, Inc.
0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 13.2% Revenue growth, TTM YoY, FY23 Q4: 12.2% Revenue growth, TTM YoY, FY24 Q1: 10.9% Revenue growth, TTM YoY, FY24 Q2: 10.1% Revenue growth, TTM YoY, FY24 Q3: 9.1% Revenue growth, TTM YoY, FY24 Q4: 7.7% Revenue growth, TTM YoY, FY25 Q1: 5.5% Revenue growth, TTM YoY, FY25 Q2: 5.6% Revenue growth, TTM YoY, FY25 Q3: 4.6% Revenue growth, TTM YoY, FY25 Q4: 5.0% Revenue growth, TTM YoY, FY26 Q1: 6.8% Revenue growth, TTM YoY, FY26 Q2: 4.3% 4.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 13.2%
FY23 Q4 12.2%
FY24 Q1 10.9%
FY24 Q2 10.1%
FY24 Q3 9.1%
FY24 Q4 7.7%
FY25 Q1 5.5%
FY25 Q2 5.6%
FY25 Q3 4.6%
FY25 Q4 5.0%
FY26 Q1 6.8%
FY26 Q2 4.3%
Operating margin (TTM) Acadia Healthcare Company, Inc.
15% 20% 25% 30% FY17 Q4 FY18 Q2 FY18 Q4 FY19 Q2 FY20 Q1 Operating margin (TTM), FY17 Q4: 21.3% Operating margin (TTM), FY18 Q1: 21.2% Operating margin (TTM), FY18 Q2: 20.9% Operating margin (TTM), FY18 Q3: 20.5% Operating margin (TTM), FY18 Q4: 19.7% Operating margin (TTM), FY19 Q1: 21.2% Operating margin (TTM), FY19 Q2: 23.1% Operating margin (TTM), FY19 Q3: 25.6% Operating margin (TTM), FY19 Q4: 29.2% Operating margin (TTM), FY20 Q1: 28.7% 28.7%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q4 21.3%
FY18 Q1 21.2%
FY18 Q2 20.9%
FY18 Q3 20.5%
FY18 Q4 19.7%
FY19 Q1 21.2%
FY19 Q2 23.1%
FY19 Q3 25.6%
FY19 Q4 29.2%
FY20 Q1 28.7%
FCF margin (TTM) Acadia Healthcare Company, Inc.
-20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 3.0% FCF margin (TTM), FY23 Q4: 1.3% FCF margin (TTM), FY24 Q1: -13.5% FCF margin (TTM), FY24 Q2: -15.0% FCF margin (TTM), FY24 Q3: -15.9% FCF margin (TTM), FY24 Q4: -17.8% FCF margin (TTM), FY25 Q1: -8.2% FCF margin (TTM), FY25 Q2: -9.6% FCF margin (TTM), FY25 Q3: -10.6% FCF margin (TTM), FY25 Q4: -13.3% FCF margin (TTM), FY26 Q1: -8.7% FCF margin (TTM), FY26 Q2: -4.0% -4.0%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 3.0%
FY23 Q4 1.3%
FY24 Q1 -13.5%
FY24 Q2 -15.0%
FY24 Q3 -15.9%
FY24 Q4 -17.8%
FY25 Q1 -8.2%
FY25 Q2 -9.6%
FY25 Q3 -10.6%
FY25 Q4 -13.3%
FY26 Q1 -8.7%
FY26 Q2 -4.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 2,811 2,836 1,905 2,008 2,090 2,314 2,610 2,929 3,154 3,313 3,368
EBITDA 744 747 674 674 — — — — — — —
Operating income 609 604 594 586 — — — — — — —
Net income 6 200 −176 109 −672 191 273 −22 256 −1,103 −1,126
Diluted EPS $0.07 $2.30 −$2.01 $1.24 −$7.59 $2.10 $2.98 −$0.24 $2.78 −$12.16 −$12.42
Growth (year on year)
Revenue — +0.9% −32.8% +5.4% +4.1% +10.7% +12.8% +12.2% +7.7% +5.0% +4.3%
EBITDA — +0.5% −9.8% −0.0% — — — — — — —
Operating income — −0.7% −1.8% −1.3% — — — — — — —
Net income — — −187.9% — −717.1% — +43.3% −107.9% — −531.4% −908.8%
Diluted EPS — — −187.4% — −712.1% — +41.9% −108.1% — −537.4% −917.9%
Margins
EBITDA margin 26.5% 26.4% 35.4% 33.5% — — — — — — —
Operating margin 21.7% 21.3% 31.2% 29.2% — — — — — — —
Net margin 0.2% 7.0% −9.2% 5.4% −32.2% 8.2% 10.5% −0.7% 8.1% −33.3% −33.4%
Free-cash-flow margin 1.9% 4.4% 8.4% 5.0% 20.8% 5.6% 3.2% 1.3% −17.8% −13.3% −4.0%
Cash flow
Cash from operations 361 400 414 333 659 374 381 462 130 132 211
Capital spending 307 274 253 233 225 245 296 424 690 572 345
Free cash flow 54 125 161 100 434 130 84 38 −561 −440 −134
Stock-based pay 28 23 22 17 23 38 30 32 37 32 31
Free cash flow after stock pay 26 102 139 83 411 92 55 6 −598 −472 −165
Balance sheet
Cash 57 67 51 100 379 134 98 100 76 133 171
Total debt 3,348 3,290 3,235 3,180 3,153 1,512 1,398 1,382 1,966 2,517 2,415
Net debt (negative = net cash) 3,291 3,223 3,184 3,081 2,775 1,378 1,301 1,282 1,890 2,384 2,243
Diluted shares 86m 87m 87m 88m 89m 91m 92m 91m 92m 91m 91m
Returned to shareholders
Buybacks — — — — — — — — — 50 —
Total returned — — — — — — — — — 50 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 6 checks passed · June 30, 2026
What it owns · $5.5bn
Short-term assets $845mLonger-term assets $4.7bn
What it owes, and who funded it · $5.3bn
Short-term liabilities $538mLonger-term liabilities $2.8bnShareholders' equity $2.0bn
  • Short-term assets cover short-term liabilities $845m of assets due within a year against $538m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $845m short-term assets against $2.8bn of longer-dated liabilities.
  • More cash than debt $171m of cash against $2.4bn of debt.
  • Debt below 40% of shareholders' equity Debt is 122% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 59% to 122% over five years.
  • A year's operating cash flow covers at least 20% of debt $211m of operating cash flow against $2.4bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Acadia Healthcare Company, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$50M
Returned to shareholders
-11%
of free cash flow
Diluted share count
−1.1%
year over year
Total shareholder yield
1.9%
dividends 0.0% + buybacks 1.9% of market value
Days sales outstanding
51 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care facilities
Last 12 months unless stated ACHC SGRY BKD CON PACS ENSG Median
Revenue, last 12 months $3.4bn $3.4bn $3.1bn $2.3bn $5.6bn $5.7bn $3.1bn
Revenue growth, last 12 months 4.3% 4.0% −4.4% 14.0% 15.2% 17.5% 14.0%
Revenue growth, 3-year average 6.6% 8.1% 1.0% — — 16.8% 8.1%
Revenue growth, latest quarter −0.4% 2.7% −11.6% 10.0% 9.1% 14.5% 8.6%
Gross margin — 23.1% 26.9% — — 21.2% 21.2%
Operating margin 28.7% 11.4% 3.5% 16.4% 7.4% 9.0% 9.0%
Operating margin, 3-year average 23.7% 11.5% 1.8% 15.9% 5.2% 8.0% 7.9%
Net margin −33.4% −2.6% −4.5% 8.7% 4.8% 7.0% 4.8%
Cash from operations / revenue 6.3% 7.7% 7.3% 14.7% 10.3% 12.3% 7.7%
Free-cash-flow margin −4.0% 5.6% 0.8% 11.7% 8.2% 10.1% 4.7%
Free-cash-flow margin, 3-year average −9.5% 6.0% −0.5% 10.2% 5.9% 8.1% 5.9%
Stock pay / revenue 0.9% 0.3% 0.4% 0.6% 1.3% 1.1% 0.6%
Change in share count −1.1% 1.3% 3.7% 1.6% −4.5% 1.3% 0.9%

Median of all 13 companies we cover in health care facilities. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

13 health care facilities companies
Measure Company Peer median Rank
Revenue growth Growth 4.3% 14.0% 11 of 13
Change in growth rate Growth -2.5pp -1.4pp 10 of 13
Net margin Profitability -33.4% 4.8% 13 of 13
Free-cash-flow margin Cash generation -4.0% 4.7% 9 of 13
Stock pay as % of revenue Cash generation 0.9% 0.6% 8 of 12
Long-term debt as % of assets Balance sheet 42.9% 37.7% 8 of 13
Change in share count Balance sheet -1.1% 0.9% 5 of 13
Days sales outstanding Balance sheet 51 days 48 days 8 of 12

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$4B
Institutions reporting
309
Shares held vs prior quarter
▲ 1.4%
Positions opened / closed
63 / 46

Top buyers and sellers, Q2 2026: 157 institutions bought and 144 sold ; the biggest buyer was Blackrock, Inc (+3.3M shares) and the biggest seller Khrom Capital Management LLC (−4.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $442M 15.0M 11.1% ▲ 28.0%
Wellington Management Group LLP $169M 5.7M 4.3% ▼ 36.9%
Vanguard Portfolio Management LLC $159M 5.4M 4.0% ▲ 6.1%
FMR LLC $148M 5.0M 3.7% ▼ 27.0%
Carronade Capital Management, LP $141M 4.8M 3.5% ▲ 103.8%
Morgan Stanley $134M 4.5M 3.4% ▲ 1.0%
Deerfield Management Company, L.P. $133M 4.5M 3.4% 0.0%
Dme Capital Management, LP $130M 4.4M 3.3% ▼ 2.6%
Farallon Capital Management, L.L.C. $125M 4.2M 3.1% ▲ 143.0%
Abrams Bison Investments, LLC $123M 4.2M 3.1% ▼ 4.9%
UBS Group AG $119M 4.0M 3.0% ▲ 42.7%
Dimensional Fund Advisors LP $119M 4.0M 3.0% ▲ 55.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Acadia Healthcare Company, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Acadia Healthcare Company, Inc. disclosed in the last 12 months; 2 earlier trades on record.

  • Susie Lee(D-NV 3):Sale (full), $1,001 - $15,000, traded November 30, 2022, filed December 29, 2022
  • Peter Meijer(R-MI 3):Sale (full), $1,001 - $15,000, traded February 16, 2021, filed March 16, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around October 8, 2026 estimated from the company's past filing pattern, not announced

  • July 28, 2026
  • April 29, 2026
  • February 25, 2026
  • January 13, 2026
  • November 5, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Acadia Healthcare Company, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Acadia Healthcare Company, Inc. in brief

What does Acadia Healthcare Company, Inc. do?
Acadia Healthcare Company, Inc. is a US-listed company in the health care facilities industry. Its financial year ends in December.
What is Acadia Healthcare Company, Inc.'s stock ticker?
Acadia Healthcare Company, Inc. trades under the ticker ACHC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Acadia Healthcare Company, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Acadia Healthcare Company, Inc. reported revenue of $3.4B, 4.3% higher than a year earlier, according to its SEC filings.
What is Acadia Healthcare Company, Inc.'s free cash flow?
Acadia Healthcare Company, Inc.'s free-cash-flow margin is -4.0% of revenue over the trailing twelve months, ranking 9 of the 13 health care facilities companies we cover.
Who are Acadia Healthcare Company, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Wellington Management Group LLP and Vanguard Portfolio Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Acadia Healthcare Company, Inc. buying back stock, and does it pay a dividend?
Acadia Healthcare Company, Inc. spent $50M on share repurchases over the trailing twelve months, and its diluted share count fell 1.1% over the year.
What is Acadia Healthcare Company, Inc.'s market cap?
On November 2, 2026, Acadia Healthcare Company, Inc.'s market capitalisation was about $2.7B and net debt of $2.2B. Market figures come from third-party market data and may be delayed.
How much debt does Acadia Healthcare Company, Inc. have?
Acadia Healthcare Company, Inc.'s debt-to-equity ratio is 122.0%, from its latest balance sheet (58.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Acadia Healthcare Company, Inc.'s competitors?
In our Health Care Facilities peer group, the companies closest to Acadia Healthcare Company, Inc. are Surgery Partners, Inc., Brookdale Senior Living Inc., Concentra Group Holdings Parent, Inc., Pacs Group, Inc. and Ensign Group, Inc. The side-by-side comparison below sets their revenue, margins and growth against Acadia Healthcare Company, Inc.'s.
When is Acadia Healthcare Company, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Acadia Healthcare Company, Inc. announces its own schedule.